Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma

Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma

Primary effusion lymphoma is a rare and aggressive large B-cell lymphoma presenting as malignant effusion with poor prognosis. Although it is more prevalent among HIV patients, it has also been described in non-HIV immunocompromised individuals. Given its rarity, there are no large randomized trials...

Full description

Bibliographic Details
Main Authors: Joana Ferra, Filipa Mousinho, Francisca Miranda, Sandra André, Celina Afonso, Fernando Nogueira
Format: Article
Language:English
Published: SMC MEDIA SRL 2021-02-01
Series:European Journal of Case Reports in Internal Medicine
Subjects:
primary effusion lymphoma
brentuximab vedotin
non-hiv
Online Access:https://www.ejcrim.com/index.php/EJCRIM/article/view/2345
id doaj-ba5db930856f4cdcb1e875567445ccd4
record_format Article
spelling doaj-ba5db930856f4cdcb1e875567445ccd42021-02-26T08:40:16ZengSMC MEDIA SRLEuropean Journal of Case Reports in Internal Medicine2284-25942021-02-0110.12890/2021_0023451961Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion LymphomaJoana Ferra0Filipa Mousinho1Francisca Miranda2Sandra André3Celina Afonso4Fernando Nogueira5Pneumology Department, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, E.P.E., PortugalHematology Department, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, E.P.E., PortugalHematology Department, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, E.P.E., PortugalPneumology Department, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, E.P.E., PortugalHematology Department, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, E.P.E., PortugalPneumology Department, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, E.P.E., PortugalPrimary effusion lymphoma is a rare and aggressive large B-cell lymphoma presenting as malignant effusion with poor prognosis. Although it is more prevalent among HIV patients, it has also been described in non-HIV immunocompromised individuals. Given its rarity, there are no large randomized trials regarding the best therapeutic option. The choice of therapy is based on retrospective studies, case reports and preclinical data. We present the case of a non-HIV patient with relapsed disease after treatment with CHOP who was then successfully treated with brentuximab vedotin, achieving complete remission.https://www.ejcrim.com/index.php/EJCRIM/article/view/2345primary effusion lymphomabrentuximab vedotinnon-hiv
collection DOAJ
language English
format Article
sources DOAJ
author Joana Ferra
Filipa Mousinho
Francisca Miranda
Sandra André
Celina Afonso
Fernando Nogueira
spellingShingle Joana Ferra
Filipa Mousinho
Francisca Miranda
Sandra André
Celina Afonso
Fernando Nogueira
Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
European Journal of Case Reports in Internal Medicine
primary effusion lymphoma
brentuximab vedotin
non-hiv
author_facet Joana Ferra
Filipa Mousinho
Francisca Miranda
Sandra André
Celina Afonso
Fernando Nogueira
author_sort Joana Ferra
title Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
title_short Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
title_full Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
title_fullStr Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
title_full_unstemmed Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
title_sort use of brentuximab vedotin in a non-hiv patient with primary effusion lymphoma
publisher SMC MEDIA SRL
series European Journal of Case Reports in Internal Medicine
issn 2284-2594
publishDate 2021-02-01
description Primary effusion lymphoma is a rare and aggressive large B-cell lymphoma presenting as malignant effusion with poor prognosis. Although it is more prevalent among HIV patients, it has also been described in non-HIV immunocompromised individuals. Given its rarity, there are no large randomized trials regarding the best therapeutic option. The choice of therapy is based on retrospective studies, case reports and preclinical data. We present the case of a non-HIV patient with relapsed disease after treatment with CHOP who was then successfully treated with brentuximab vedotin, achieving complete remission.
topic primary effusion lymphoma
brentuximab vedotin
non-hiv
url https://www.ejcrim.com/index.php/EJCRIM/article/view/2345
work_keys_str_mv AT joanaferra useofbrentuximabvedotininanonhivpatientwithprimaryeffusionlymphoma
AT filipamousinho useofbrentuximabvedotininanonhivpatientwithprimaryeffusionlymphoma
AT franciscamiranda useofbrentuximabvedotininanonhivpatientwithprimaryeffusionlymphoma
AT sandraandre useofbrentuximabvedotininanonhivpatientwithprimaryeffusionlymphoma
AT celinaafonso useofbrentuximabvedotininanonhivpatientwithprimaryeffusionlymphoma
AT fernandonogueira useofbrentuximabvedotininanonhivpatientwithprimaryeffusionlymphoma
_version_ 1724249718314237952

Similar Items